AlphaCentric Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$353K Buy
1,432
+42
+3% +$10.7K 0.31% 101
2026
Q2
$418K Buy
1,390
+20
+1% +$6.03K 0.35% 100
2026
Q1
$453K Buy
1,370
+75
+6% +$25.5K 0.45% 78
2025
Q4
$515K Buy
+1,295
New +$573K 0.51% 60

Other funds holding ALNY

AlphaCentric Advisors's ALNY Position: Q3 2026 in Review

AlphaCentric Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 3% in Q3 2026, buying an estimated $10.7K and bringing the position to 1,432 shares worth $353K. The position accounts for 0.31% of the portfolio, ranked #101.

AlphaCentric Advisors first reported a position in ALNY in Q4 2025 and has held it in 4 quarters since. The position peaked at $515K in Q4 2025. 640 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • AlphaCentric Advisors held 1,432 shares of Alnylam Pharmaceuticals worth $353K as of Q3 2026.
  • AlphaCentric Advisors bought 42 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $10.7K.
  • Alnylam Pharmaceuticals made up 0.31% of AlphaCentric Advisors's portfolio in Q3 2026, its #101 holding.
  • AlphaCentric Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • AlphaCentric Advisors's Alnylam Pharmaceuticals position peaked at $515K in Q4 2025.
  • 640 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.